01/31/19

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

01/28/19

Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement

01/03/19

Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab

12/17/18

Kiniksa Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference

12/11/18

Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial

12/06/18

Kiniksa Provides Update on U.S. FDA Review of Investigational New Drug Application for Mavrilimumab in Giant Cell Arteritis

11/01/18

Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress

09/15/18

Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology

08/29/18

Kiniksa to Present Late-Breaking KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology

08/28/18

Kiniksa Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference

08/06/18

Kiniksa Reports Second Quarter 2018 Financial Results and Pipeline Progress

08/02/18

Kiniksa Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference

06/25/18

Kiniksa Pharmaceuticals, Ltd. Announces Exercise of the Underwriters’ Option to Purchase Additional Shares

06/14/18

Kiniksa Pharmaceuticals to Present at the JMP Securities 2018 Life Sciences Conference

05/29/18

Kiniksa Pharmaceuticals, Ltd. Announces Closing of Initial Public Offering

05/23/18

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering

12/21/17

Kiniksa Pharmaceuticals to Present at 36th Annual J.P. Morgan Healthcare Conference

12/20/16

Sanj K. Patel to Introduce Kiniksa Pharmaceuticals at 35th Annual J.P. Morgan Healthcare Conference